02/07/2012 09:59 .
Having detected therapeutic activity in preclinical and clinical trials with PM01183 in breast cancer, PharmaMar is commencing a Phase II trial with the drug.
The endpoint is to confirm PM01183's activity in patients with breast cancer.
Hospitals in Spain and the US are participating in this trial.
Madrid, 2 July 2012: After launching Phase II trials in pancreatic and platinum- resistant ovarian cancer, PharmaMar is commencing a Phase II trial with its PM01183 compound in breast cancer. The endpoint is to evaluate the compound's antitumour activity as second- to fourth-line treatment in patients with this illness.
At least 50 (first phase) and at most 117 evaluable patients will be treated in the hospitals participating in this important trial.